

BeiGene's Global Internal Discovery Pipeline

For our full pipeline, including single-country trials, please visit beigene.com/our-science-and-medicines/pipeline
 *Enrolling in the U.S.; **First-in-human trial, healthy subjects; †This combination is being studied in the third cohort of NCT03336333
 ^SMAC = second mitochondrial-derived activator of caspase

Asset	Program	Phase 1	Phase 2	Phase 3
Zanubrutinib (BTK inhibitor)	monotherapy			1L and R/R WM R/R CLL/SLL
	+ rituximab		Mature B-cell malignancies R/R MZL	
	+ CYP3A inhibitors	B-cell malignancies		1L MCL and R/R MZL
	+/- venetoclax (Bcl-2 inhibitor)†			1L CLL/SLL
	+ obinutuzumab (anti-CD20)		R/R FL	
Tislelizumab (anti-PD-1)	monotherapy		Previously treated HCC, R/R cHL	2L advanced ESCC, 1L HCC, 2L/3L NSCLC
	+ chemotherapy			1L advanced ESCC, 1L GC/GEJC
	+ zanidatamab (anti-HER2 bi-specific antibody) + chemotherapy			GEA
	+ surufatinib (VEGFR, FGFR, CSF-1R inhibitor)		Solid tumors	
	+ fruquintinib (VEGFR)*		Solid tumors	
Ociperlimab (anti-TIGIT)	+ tislelizumab		2L PD-L1+ ESCC 2/3 L Cervical cancer	1L PD-L1 high NSCLC
	+ tislelizumab + chemotherapy	Solid tumors		
	+ tislelizumab + concurrent chemoradiotherapy		1L NSCLC	1L unresectable NSCLC
			1L LS-SCLC	
Surzeblimab (BGB-A425, anti-TIM-3)	+ tislelizumab		Solid tumors	
BGB-A445 (anti-OX40)	+ tislelizumab	Solid tumors		
BGB-10188 (PI3K inhibitor)	+ tislelizumab		Solid tumors	
	+/- zanubrutinib		B-cell lymphoid malignancies	
	+/- tislelizumab		B-cell malignancies	
BGB-15025 (HPK1 inhibitor)	+ tislelizumab	Solid tumors		
Pamiparib (PARP 1/2 inhibitor)	monotherapy			1L maintenance platinum-sensitive GC
	+ temozolomide	Solid tumors		
BGB-3245 (BRAF inhibitor)	monotherapy	Solid tumors with <i>BRAF</i> mutations		
Lifirafenib (RAF inhibitor)	+ mirdametinib (MEK inhibitor)	Solid tumors		
BGB-11417 (Bcl-2 inhibitor)	+/- zanubrutinib	Mature B-cell malignancies		
	monotherapy		R/R MCL	
	+ azacitidine +/- posaconazole		Myeloid malignancies	
	+ dexamethasone +/- carfilzomib		R/R multiple myeloma with t(11;14)	
BGB-16673 (BTK-targeted CDAC)	monotherapy	B-cell malignancies		
BGB-23339 (TYK2 inhibitor)**	monotherapy	Inflammation and immunology		
BGB-24714 (SMAC mimetic)*	+/- chemotherapy	Solid tumors		
BGB-B167 (CEA x 4-1BB bispecific)	+/- tislelizumab	Solid tumors		